Sat.Apr 08, 2023 - Fri.Apr 14, 2023

article thumbnail

The Future of Pharma Production, Manufacturing and Packaging

Drug Discovery Today

Through a series of exclusive interviews and a survey of industry insiders, Connect in Pharma names the top pharmaceutical and manufacturing-related trends of 2023

Packaging 113
article thumbnail

Diversity content roundup for National Minority Health Month

Antidote

Every April is National Minority Health Month , organized by the U.S. Department of Health and Human Services. This month is intended to highlight the focus on improving the health of racial and ethnic minorities by reducing health disparities and increasing equal access to care.

98
article thumbnail

DCI’s Top 15 Specialty Pharmacies of 2022: Five Key Trends About Today’s Marketplace

Drug Channels

In Drug Channels Institute’s list of the top 15 pharmacies of 2022 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. To complement that broader ranking, we rummaged around our DreamHouse to update our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues in 2022.

article thumbnail

New patent expiration for Wyeth Pharms drug ZOSYN IN PLASTIC CONTAINER

Drug Patent Watch

Annual Drug Patent Expirations for ZOSYN+IN+PLASTIC+CONTAINER Zosyn In Plastic Container is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from two suppliers. There… The post New patent expiration for Wyeth Pharms drug ZOSYN IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 88
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Working Hours and Fatigue: Meeting the Needs of American Workers and Employers

NIOSH Science Blog: Drugs

In November 2022, the American Journal of Industrial Medicine (AJIM) published a special issue focusing on work-related fatigue. The issue explores factors that may increase work-related fatigue and actions to reduce work-related injuries and illnesses. [1] This issue is a result of discussions and collaborations from the 2019 NIOSH Working Hours, Sleep and Fatigue Forum and also pulls from reports by the National Institute for Occupational Safety and Health (NIOSH) on long work hours and shift

78
article thumbnail

Bring Out Your Meds! Bring Out Your Meds!

FDA Law Blog: Biosimilars

By Larry K. Houck — Eric Idle, as a body collector, immortalized the phrase, “Bring out your dead,” in the 1975 comedy classic, Monty Python and the Holy Grail. The Drug Enforcement Administration (“DEA”) could voice a modern variation, “Bring out your meds,” as the agency and its law enforcement partners host local drop-off locations nationwide for safe disposal of unneeded medication on Saturday, April 22, 2023, from 10:00 a.m. to 2:00 p.m. local time.

Drugs 57

More Trending

article thumbnail

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Covalent Modifiers

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Satoshi Yamashita, Kosuke Egami, Yoshihiro Shibata, Ikuo Yamamiya, Fumiaki Yamashita, Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, Toshiharu Komori, Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai, and Takeshi Sagara ACS Medicinal Chemistry Letters 2023 14 (4), 396-404 DOI: 10.1021/acsmedchemlett.3c00006 Deregulating fibroblast growth factor receptor (FGFR) signaling is a promising strategy for cancer therapy.

article thumbnail

Research Shows Benefits of Reduced Aerial Ladder Rung Spacing

NIOSH Science Blog: Drugs

As a critical part of their job, firefighters often climb aerial ladders up to 30 meters (or 98 feet) long and positioned at various angles. Aerial ladders are mechanically-operated, long, extendable ladders mounted on fire trucks and are used to reach high places for extinguishing fires and rescue operations. While climbing, firefighters typically wear heavy protective equipment and may also carry additional equipment related to fighting fires or rescuing occupants from burning buildings.

article thumbnail

A Long Strange Trip: Companion Bills Would Facilitate Psychedelics Research

FDA Law Blog: Biosimilars

By Larry K. Houck — Drugs and substances classified within schedule I of the federal Controlled Substances Act (“CSA”) by definition have a high potential for abuse, no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision. 21 U.S.C. § 812(b)(1). Last month bipartisan legislation, S. 689 and H. 1393 introduced in the Senate and the House, would facilitate removing barriers to research and compassionate use for schedule I co

article thumbnail

Which pharmaceutical companies have the most cream dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs… The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Data Challenges (and Solutions) for Externally Controlled Trials

Cytel

Real-world data and evidence are increasingly being used in health care decisions and publications. However, there are challenges in identifying suitable data for external control arms, and researchers need to consider solutions to address issues like data quality, bias, and selection bias when using real-world evidence for comparative efficacy analyses.

Trials 52
article thumbnail

Biotech Funding: Times Are Tough, Maybe For The Better

LifeSciVC

Times remain tough for private biotech venture capital funding. Access to capital is more constrained than it’s been in years, and companies are starting to feel the pinch. Yet, despite the pain after a cycle of excess, perhaps this return towards more discipline should be embraced. As has already been widely reported , aggregate venture capital funding in the first quarter of 2023 is well off its peaks of 2020-2022.

article thumbnail

Genetic Signature for Drug Addiction Revealed in New Analysis of More Than A Million Genomes

PLOS: DNA Science

Drug addiction is prevalent and deadly. In the US in 2021, more than 46 million people aged 12 or older had addiction to at least one substance, yet only 6.3% received treatment, according to the National Institute on Drug Abuse (NIDA). A complex mix of gene variants and environmental factors lies behind the compulsion to repeatedly take a drug and increase the dose, despite knowing the dangers.

DNA 52
article thumbnail

New patent expiration for Adhera drug PRESTALIA

Drug Patent Watch

Annual Drug Patent Expirations for PRESTALIA Prestalia is a drug marketed by Adhera and is included in one NDA. There are two patents protecting this drug and one Paragraph IV… The post New patent expiration for Adhera drug PRESTALIA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

HPM’s John Claud to host webinar for FDANews: “Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC.”

FDA Law Blog: Biosimilars

On Thursday, April 20, from 1:30-3:00pm, John Claud of Hyman, Phelps & McNamara, P.C. will present a webinar entitled “ Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC.” John will provide participants with a greater understanding of new guidance implications, as well as recent guidance on delaying, denying, limiting, or refusing an inspection, and the DOJ’s revised Corporate Enforcement Policy, which altered the way the agency reviews corporate criminal prosecution

FDA 52
article thumbnail

2023 drug discovery forecast: emerging trends and disruptors revolutionising the industry

Drug Target Review

Artificial intelligence (AI) AI has seen quite a boom in the last couple of years, overcoming challenges such as limited and low-quality data. Researchers can avoid numerous delays by employing AI for drug discovery, often using computational approaches in combination with their own techniques, for a faster and smoother path to the clinic. 1 Getting to grips with what AI can do and how best to acquire and utilise its skills.

Drugs 52
article thumbnail

Reliable Alternatives for Drug Discovery: Questions and Answers

Crown Bioscience

The development of new drugs and biological products has traditionally mandated animal testing, but the FDA Modernization Act 2.0 allows for alternative non-clinical testing, allowing reliable alternatives for drug discovery and biological product applications.

article thumbnail

New patent for Alcon Labs drug EYSUVIS

Drug Patent Watch

Annual Drug Patent Expirations for EYSUVIS Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent for Alcon Labs drug EYSUVIS appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Jim Bob Ward Appointed as Chief Strategy Officer at eClinical Provider Crucial Data Solutions

Crucial Data Solutions

RENO, Nev.–(BUSINESS WIRE)–Crucial Data Solutions (CDS), a provider of innovative technologies to advance clinical research, announced today that industry veteran. The post Jim Bob Ward Appointed as Chief Strategy Officer at eClinical Provider Crucial Data Solutions appeared first on Crucial Data Solutions.

article thumbnail

Overcoming the Shared Effect Modifier Assumption with Network Meta-Interpolation

Cytel

Commonly used methods to handle the complexities of effect modification in indirect treatment comparisons (ITCs) often rely on the shared effect modifier (SEM) assumption, that is, that the effect modifiers impact a set of treatments in the evidence network in the same way. However, it has been argued that this assumption is limiting and often unreasonable to make.

article thumbnail

Unlocking the Potential of Radiosensitizers with Patient-derived Tumor Organoids

Crown Bioscience

Although radiotherapy (also called radiation therapy ) is an important aspect of cancer treatment, it has limitations, including its potential for damaging healthy tissues, induction of radiotherapy resistance, requiring well-oxygenated tumors, and potentially increasing the risk for generating metastases. There remains an unmet need for ways to enhance radiotherapy.

article thumbnail

New patent for HIKMA drug PHENYLEPHRINE HYDROCHLORIDE

Drug Patent Watch

Annual Drug Patent Expirations for PHENYLEPHRINE+HYDROCHLORIDE Phenylephrine Hydrochloride is a drug marketed by Akorn, Mankind Pharma, Paragon Bioteck, Accord Hlthcare, Amneal, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd,… The post New patent for HIKMA drug PHENYLEPHRINE HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

How is Your Learning Technology Stack Delivering Value?

ACTO

An insightful piece from the Life Sciences Trainers & Educators Network (LTEN) focusing on Building the Right Learning Technology Architecture sparked a conversation at ACTO about determining the value that your learning technology stack delivers and the importance of defining that correctly. In the LTEN article, Rich Baron aptly stated, “It’s not about which technology is best.

Science 52
article thumbnail

Patient Recruitment from a Site Perspective: Technology Meeting Today’s Challenges

Advarra

Effective participant recruitment is crucial to a successful clinical trial, but recruiting eligible participants in sufficient numbers has long been a challenge. As trials become more complex, and calls for appropriate diversity in participant populations increase, the problem is intensifying. Smaller sites often have the most difficulty, and fewer resources for meeting the challenges.

article thumbnail

Asthma insights from 37,000 patients [whitepaper]

Antidote

Asthma is a condition that can impact anyone — and currently, it affects over 26.5 million people in the United States. In spite of available treatments, asthma is responsible for 1.3 million emergency room visits and over 3,500 deaths every year. Additionally, asthma’s impact is not evenly distributed; the condition impacts a disproportionate number of women, children, and minority populations, and has a direct correlation with an individual’s socioeconomic status.

article thumbnail

New patent expiration for Wyeth Pharms drug ZOSYN

Drug Patent Watch

Annual Drug Patent Expirations for ZOSYN Zosyn is a drug marketed by Wyeth Pharms and is included in two NDAs. There are three patents protecting this drug and two Paragraph… The post New patent expiration for Wyeth Pharms drug ZOSYN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Is It Too Soon To Start Talking about a Cure for Addiction?

National Institute on Drug Abuse: Nora's Blog

Is It Too Soon To Start Talking about a Cure for Addiction? mfleming Mon, 04/10/2023 - 14:43 Nora's Blog April 13, 2023 Image Getty Images/ AleksandarGeorgiev This article originally appeared in the Milken Institute’s Power of Ideas series. Our country remains in the grips of an opioid crisis claiming more than 100,000 lives every year. Rising mortality associated with drug addiction and excessive drinking is among the major factors contributing to declining life expectancy.

article thumbnail

Codon Digest: CAR-T Therapy for Neuroblastoma

Codon

This is Codon Digest, my weekly roundup of research, news, and industry highlights about the future of biology. Also: I’ve turned on paid subscriptions. No plans for exclusive content just yet, but if you’d like to support my work for $3 or $5 per month, please consider it. My goal is to reach 100 supporters! Thank you for being here. Support Codon for $3 per month.

article thumbnail

ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

Zobio

In person From 10 to 13 June Michael Nyman attended ACSMEDI-EFMC Medicinal Chemistry Frontiers symposium in Boston. The conference was co-organized as a collaboration between the ACS (American Chemical Society), MEDI (Division of Medicinal Chemistry) and the EFMC (European Federation for Medicinal Chemistry and Chemical Biology). The meeting attracted a highly targeted audience composed of experts, researchers and.

article thumbnail

New patent expiration for Janssen Prods drug EDURANT

Drug Patent Watch

Annual Drug Patent Expirations for EDURANT Edurant is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are four patents… The post New patent expiration for Janssen Prods drug EDURANT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Driving sustainability in drug discovery: A community approach

Elrig

Driving sustainability in drug discovery: A community approach Driving sustainability in drug discovery: A community approach Author: Sanj Kumar, CEO, ELRIG UK The pharma and biotech industry is growing. While this brings the promise of new therapeutics for currently untreatable diseases, the increasing environmental impact of the industry cannot be ignored.

Drugs 40
article thumbnail

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

The Pharma Data

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

article thumbnail

ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

Zobio

In person From 10 to 13 June Michael Nyman attended ACSMEDI-EFMC Medicinal Chemistry Frontiers symposium in Boston. The conference was co-organized as a collaboration between the ACS (American Chemical Society), MEDI (Division of Medicinal Chemistry) and the EFMC (European Federation for Medicinal Chemistry and Chemical Biology). The meeting attracted a highly targeted audience composed of experts, researchers and.